SUBJECT_ID
Item
De-identified Subject ID
string
C4684638 (UMLS CUI [1,1])
C2348585 (UMLS CUI [1,2])
Cohort
Item
Patient's cohort in current study
string
C0599755 (UMLS CUI [1,1])
C0947630 (UMLS CUI [1,2])
Histology
Item
Tumor histology
string
C1516204 (UMLS CUI [1,1])
Age
Item
Patient's age
text
C0001779 (UMLS CUI [1,1])
Item
Gender of participant
text
C0079399 (UMLS CUI [1,1])
Code List
Gender of participant
CL Item
Female (F)
C0086287 (UMLS CUI [1,1])
CL Item
Male (M)
C0086582 (UMLS CUI [1,1])
CL Item
Not applicable (NA)
C1272460 (UMLS CUI [1,1])
Smoking
Item
Self-reported smoking status
string
C1519386 (UMLS CUI [1,1])
C2700446 (UMLS CUI [1,2])
Pack-years
Item
Product of number of packs per day and number of years smoked
text
C3694145 (UMLS CUI [1,1])
C4288114 (UMLS CUI [1,2])
PD-L1
Item
Programmed death-ligand 1 (PD-L1) expression
string
C5781048 (UMLS CUI [1,1])
Priors
Item
Prior courses of cytotoxic chemotherapy. Combination chemotherapy counted as a single course. No patient had received prior immunotherapy.
text
C1302181 (UMLS CUI [1,1])
C0237753 (UMLS CUI [1,2])
C1521750 (UMLS CUI [2,1])
C0750729 (UMLS CUI [2,2])
C0205447 (UMLS CUI [2,3])
C1298908 (UMLS CUI [3,1])
C1514463 (UMLS CUI [3,2])
C0021083 (UMLS CUI [3,3])
Dose (mg/kg)
Item
Dose (mg/kg)
text
C3174092 (UMLS CUI [1,1])
Sched
Item
Pembrolizumab dosed every 2 or 3 weeks as indicated.
text
C3658706 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C1561548 (UMLS CUI [1,3])
PFS (mos)
Item
Progression free survival in months
text
C0242792 (UMLS CUI [1,1])
C0439231 (UMLS CUI [1,2])
Resp
Item
Denotes best overall response to pembrolizumab
string
C2986560 (UMLS CUI [1,1])
C3658706 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
Durable_Clinical_Benefit
Item
Patient's clinical benefit
string
C4684590 (UMLS CUI [1,1])
Smoking_Signature
Item
Molecular smoking signature
string
C1704864 (UMLS CUI [1,1])
C0037369 (UMLS CUI [1,2])